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Human IgG4, normally the least abundant of the four subclasses of IgG in serum, displays a number of unique
biological properties. It can undergo heavy-chain exchange, also known as Fab-arm exchange, leading to the
formation of monovalent but bispecific antibodies, and it interacts poorly with FcγRII and FcγRIII, and
complement. These properties render IgG4 relatively “non-inflammatory” and have made it a suitable format
for therapeutic monoclonal antibody production. However, IgG4 is also known to undergo Fc-mediated
aggregation and has been implicated in auto-immune disease pathology. We report here the high-resolution
crystal structures, at 1.9 and 2.35 Å, respectively, of human recombinant and serum-derived IgG4-Fc. These
structures reveal conformational variability at the CH3–CH3 interface that may promote Fab-arm exchange,
and a unique conformation for the FG loop in the CH2 domain that would explain the poor FcγRII, FcγRIII and
C1q binding properties of IgG4 compared with IgG1 and -3. In contrast to other IgG subclasses, this unique
conformation folds the FG loop away from the CH2 domain, precluding any interaction with the lower hinge
region, which may further facilitate Fab-arm exchange by destabilisation of the hinge. The crystals of IgG4-Fc
also display Fc–Fc packing contacts with very extensive interaction surfaces, involving both a consensus
binding site in IgG-Fc at the CH2–CH3 interface and known hydrophobic aggregation motifs. These Fc–Fc
interactions are compatible with intact IgG4 molecules and may provide a model for the formation of
aggregates of IgG4 that can cause disease pathology in the absence of antigen.
© 2013 The Authors. Published by Elsevier Ltd. All rights reserved.Introduction
The four subclasses of human IgG display a high
degree of sequence homology in their constant
regions, yet they play distinct roles and exhibit
different patterns of receptor interactions. These
functional differences may be attributed in part not
only to the lengths and sequences of their hinge
regions, but also to subtle sequence variations in the
CH2 domain [1]. IgG1 and IgG3 play important rolesatter © 2013 The Authors. Published by Elin antibody-dependent cell-mediated cytotoxicity
(ADCC) and the activation of complement, through
binding to high affinity Fcγ receptors and C1q,
respectively [1,2]. With the exception of FcγRI,
IgG4 binds Fcγ receptors with lower affinity [2],
and in lacking the effector functions of IgG1 and
IgG3, including C1q binding, is considered to be
anti-inflammatory [3,4]; however, a clinical trial involv-
ing an IgG4 subclass antibody still gave rise to an
unexpected systemic inflammatory response [5].sevier Ltd. All rights reserved. J. Mol. Biol. (2014) 426, 630–644
631Crystal structure of Human IgG4-FcWhile IgG4 is normally the least represented IgG
subclass in serum, levels are elevated in rheumatoid
arthritis [6], IgG4-related disease (IgG4-RD) and
auto-immune pancreatitis [7,8], as well as under
conditions of chronic exposure to an antigen, or after
allergen-specific immunotherapy [9,10]. It does
however exhibit a unique property, namely the ability
for the two heavy (H) chains to disengage, forming a
“half-molecule”, and then re-assemble with H chains
of another IgG4 antibody, perhaps with different
specificity, to form a bispecific antibody that is
monovalent with respect to each specificity
[9,11,12]. This phenomenon, known as Fab-arm
exchange (FAE), occurs in vivo and is proposed to
further contribute to the anti-inflammatory properties
of IgG4 [3,13]. The core sequence of the IgG4 hinge
(residues 226–230), which promotes formation of
intra- rather than inter-H chain disulfide bonds, and
residue Arg409 at the CH3–CH3 interface, which
weakens the non-covalent association between
these domains, are requirements for FAE to occur,
and dissociation of the CH3 domains is a rate-limiting
step in the exchange mechanism [3,14–17].
Of the four IgG subclasses, IgG1 has been studied
most extensively in structural terms. There are crystal
structures for human IgG1-Fc alone (e.g., Refs. [18–
21]) and in complex with FcγRII [22], FcγRIII [23–26],
staphylococcal protein A [27], streptococcal protein G
[28], TRIM21 (tripartitemotif 21) [29], HSV-1 (herpes
simplex virus 1) Fc receptor [30] and rheumatoid
factor [31], as well as a structure of the whole anti-
body [32]. More recently, crystal structures for
human IgG2-Fc have also been reported [33,34].
However, despite its use as a therapeutic monoclo-
nal antibody and intriguing biological properties,
high-resolution structural information for IgG4 is
limited. The structure of IgG4 has been studied in
solution [35,36], and only one low-resolution crystal
structure (3.15 Å) of IgG4-Fc in complex with a
rheumatoid factor, and one high-resolution crystal
structure (1.8 Å) of the isolated CH3 domain dimer,
have been solved [17,37].
We report here the crystal structures of IgG4-Fc
obtained from papain digestion of IgG4 from patient
sera (sdFc), and recombinant IgG4-Fc (rFc), both at
substantially higher resolution (2.35 Å and 1.9 Å,
respectively) than the previous Fc study. Conse-
quently, we reveal the effects of variation in Arg409
conformations on the CH3 interface, providing a
better understanding of this controlling factor for
FAE. A novel Fc–Fc interaction is also observed that
may provide a model for the aggregation of IgG4 in
disease, and a general model for IgG aggregation in
therapeutic monoclonal antibody preparations. Fi-
nally, and unexpectedly, the FG loop in the CH2
domain of IgG4-Fc, which in other IgG subclasses is
involved in both Fcγ receptor [23,24] and C1q
binding [19], is found to adopt a conformation that
would disrupt these activities. Interaction betweenthis loop and the lower hinge region, as in IgG1,
would also be impossible, with further implications
for FAE. The structural determinants for many of the
unusual functional properties of IgG4 are thus
revealed in this study.Results
Overall structure and glycosylation
The overall IgG4-Fc domain topology resembles
that of other IgG-Fc fragments [1] and residues 236–
445 (chain A) and 236–444 (chain B), and 237–444
(chain A) and 238–443 (chain B) were built for the
recombinant IgG4-Fc (rFc) and serum-derived
IgG4-Fc (sdFc) structures, respectively. The B-fac-
tors for the CH2 domain of chain B in both structures
were higher than those for the other CH2 and CH3
domains, as were those for the N-linked oligosac-
charides attached to these two domains. A complex
biantennary core was modelled in both structures,
and with the exception of chain B of the sdFc
structure, a fucose residue, attached to the first
N-acetylglucosamine residue covalently bound to
Asn297, was also built. In both rFc and sdFc
structures, the α(1–3) oligosaccharide branch man-
nose residues form a hydrogen bond with one
another.
The sdFc structure was solved using the previ-
ously characterised Rea IgG4 myeloma protein [38].
The Rea IgG4 oligosaccharide is a 70% G(0)
glycoform that was later enzymatically galactosy-
lated to yield a 100% G(2) glycoform [39]. In both
chains, a galactose residue attached to the α(1–6)
branch forms hydrogen bonds with surrounding
protein residues, but the α(1–3) branch galactose
residue was disordered.
The terminal α(1–6) galactose residue is absent
in the rFc structure, and instead, additional water
molecules fill the space. Terminal galactose is
observed in recombinant IgG structures where protein
has been produced in CHO cells (e.g., Refs. [26] and
[30]), and we attribute the absence of galactose in the
rFc structure to the use of HEK cells [40]. Apart from
this difference in glycosylation, the overall structures
of rFc and sdFc are essentially identical.
Arg409 and the CH3–CH3 interface
Arg409 was recently identified as the key IgG4
CH3 domain residue controlling FAE [14]. In IgG1,
IgG2 and IgG3, which do not undergo FAE, this
residue is lysine. The high-resolution crystal struc-
ture of the IgG4 CH3 domain dimer showed how
Arg409 weakened the CH3–CH3 interface by dis-
rupting a network of conserved water molecules that
mediate inter-domain hydrogen bonds, reducing
632 Crystal structure of Human IgG4-Fccontact at the edge of the interface through DE loop
movement, and lowering its buried surface area [17].
The conformation of Arg409 seen in this high-
resolution CH3 dimer structure differed from that
observed in the earlier IgG4-Fc structure [37], but the
low resolution of the latter prevented any conclu-
sions from being drawn concerning conformational
variation of Arg409. However, we can now see
clearly in the two structures reported here that unlike
Lys409 in IgG1, which is conformationally conserved
in all known structures, Arg409 can indeed adopt
two alternative conformations at the interface, upon
which they have different effects (Fig. 1).
In conformation 1, found in the A chains of both rFc
and sdFc, as well as the low-resolution Fc structure,
the Arg409 guanidinium group is oriented towards
Asp399′ (of the other H chain), forming an electro-
static interaction (Fig. 1). In the rFc structure, three
conserved water molecules (W1–W3) are present at
the CH3–CH3 interface, while in the sdFc structure,
two conserved water molecules (W3–W4) are
present, and the hydrogen bond network is compa-
rable to that found in IgG1. The network is also
observed in IgG2, which does not undergo FAE,
where residue 409 is lysine [33,34]. Crucially, the rFcFig. 1. The environment of Arg409 at the CH3–CH3 interfac
domain dimer structure in pink (PDB ID 4B53 [17]), chain A (gre
structure. IgG1-Fc (PDB ID 3AVE [21]) is coloured grey. C
conformation 2 in the CH3 domain and chain B of the rFc structu
the rFc structure does not. (b) Alternative view of the two conf
Lys370′, W1, W3 and W4 are not shown.structure demonstrates the ability of W2 to bind at the
CH3–CH3 interface in the presence of Arg409. In
conformation 2, however, seen in the B chain of rFc
and the high-resolution CH3 dimer structure, the
Arg409 guanidinium group forms hydrogen bonds
with both Asp399′ (of the other H chain) and Ser400′.
In occupying the location of W2, and affecting the
conformation of Lys370′ and the position of W1,
conformation 2 disrupts the network of water mole-
cules that mediate inter-domain hydrogen bonds.
On the other hand, in chain B of the sdFc structure,
B-factors for residues at the CH3 domain surface,
close to the CH3–CH3 interface, are considerably
higher than those for the rest of the domain. The
Ser400′ side chain points away from Asn390, its
hydrogen bonding partner, and other interface
residues, including Arg409, are partially disordered.
Arg409 conformation 1 is thus more akin to an
IgG1-like CH3–CH3 interface, while conformation 2
clearly weakens the interface through disrupting the
water molecule network. The buried surface area for
the interface with conformation 2 (calculated for
residues in the vicinity of Arg409) is ~55 Å2 less
than that for an interface with Arg409 in conformation
1, which is in turn comparable to that of IgG1.e. (a) Arg409 and nearby residues are shown for the CH3
en) and chain B (yellow) of the recombinant IgG4-Fc (rFc)
onserved water molecules are labelled W1–W4. Arg409
re prevents W2 binding, while conformation 1 in chain A of
ormations adopted by Arg409 in IgG4. For clarity, Glu357,
633Crystal structure of Human IgG4-FcFc–Fc interactions revealed through
crystal packing
Interactions mediated through antibody Fc re-
gions, particularly those of the IgG4 subclass, are
of interest because they have been implicated in
disease-related immune complex formation [6,7].
Antibody aggregation is also critically important to
the therapeutic antibody market, which includes a
number of IgG4 monoclonal antibodies [41–44].
Crystal contacts in the IgG4-Fc structures were
analysed, and two extensive interfaces were identi-
fied (Fig. 2a and b). Interface I (Fig. 2a) comprises
two Fc molecules related by a twofold rotation,
buries a surface area of ~1480 Å2 and involvesFig. 2. Fc–Fc interfaces identified through crystal packing. (a
Fc molecules are related to one another by a twofold rotation.
and another Fc molecule (chain A, cyan), are depicted as sphe
The top of the CH2 domain from one Fc molecule (chain A, pin
molecule (chain A, yellow), close to the CH2–CH3 interface. In
view of the interface, showing residues Glu293, Glu294, Phe2
Ile253, Leu309, His310 and Gln311 from the second (yellow). F
through interface I can be assembled in a linear fashion. In eac
where the Fc region is connected in turn to hinge and Fab
alternately above and below the plane of assembly. (d) An asse
is formed from interactions between chain A of successive Fc m
approximate position of Fab regions from two adjacent molecucontact between CH2 and CH3 domains of different
chains. Van der Waals interactions predominate,
and there is a salt bridge (Arg255–Glu382), all of
which are duplicated due to the twofold nature of the
interaction. A PISA [45] search of the Protein Data
Bank (PDB) revealed a similar twofold related
interface in other IgG1-Fc structures, with buried
surface areas ranging from 1020 Å2 to 1990 Å2 but
virtually identical orientations of the Fc pairs.
Interface II (Fig. 2b) involves the “top” of the CH2
domain of one Fc molecule, close to Asn297 to which
oligosaccharide is attached, interacting with the “side”
of the CH2 domain of a second Fc molecule, close
to the CH2–CH3 interface; the overall orientation of the
two IgG4-Fc molecules resembles the interaction) Orientation of the two Fc molecules in interface I. The two
Interfacing residues from one Fc molecule (chain B, grey),
res. (b) Orientation of the two Fc molecules in interface II.
k) interacts with the side of the CH2 domain from another
terfacing residues are depicted as spheres. Inset: Detailed
96 and Tyr300 from the first molecule (pink), and residues
or clarity, Gln268 is not shown. (c) Fc molecules interacting
h chain, residue 327 at the N-terminus of the CH2 domain,
regions, is coloured red. Fab regions would be oriented
mbly of Fc molecules created by interface II. The assembly
olecules. Once again, residue 327 is coloured red, and the
les is indicated.
634 Crystal structure of Human IgG4-Fcbetween IgG-Fc and FcRn [46]. The buried surface
area is ~860 Å2 and hydrophobic interactions pre-
dominate [e.g., Phe296 and Tyr300 of one chain (the
“top”) and Leu309 and Ile253 (the “side”) of the other;
Fig. 2b, inset], although there are also hydrogen
bonds (e.g., Glu293–Gln311 and Glu294–His310;
Fig. 2b, inset). To our knowledge, interface II has not
been observed in any human IgG-Fc structure
reported to date, although Fc–Fc interfaces involving
residues 253 and 296 have been observed in rabbit
and mouse IgG-Fc (Fig. S1) [47,48].
The IgG4 CH2 domain FG loop adopts a different
conformation
When compared with high-resolution IgG1-Fc
structures (e.g., Refs. [19–21]), the FG loop in both
CH2 domains of IgG4-Fc is seen to adopt a quite
different conformation between residues Ser324 and
Ser331 (Fig. 3). This difference folds the FG loop
away from the CH2 domain to the extent that the C
α
atoms for residues 327 and 329 differ by 9.9 Å and
6.7 Å, respectively, compared with IgG1-Fc. The
conformation is essentially identical to that observed
in one domain of an IgG2-Fc mutant structure (the
top portion of the other CH2 domain was disordered),
where the IgG4-Fc CH2 FG loop was recreated
through two point mutations [34].
However, comparison of main chain φ and ψ
torsion angles reveals that values are only substan-
tially different for two residue pairs, 326 and 327
(Lys–Ala in IgG1, Lys–Gly in IgG4) and 330 and 331Fig. 3. Conformational differences in the CH2 FG loop.
Superposition of the recombinant IgG4-Fc (rFc) structure
(purple) on that of IgG1-Fc (grey) (PDB ID 3AVE [21])
reveals the unique FG loop conformation found in IgG4.
The distance between Pro329 (Cα atoms) in the two
structures is indicated, as well as that for Ala327 (IgG1)
and Gly327 (IgG4), highlighting the extent of the differ-
ences. The effect on the positions of BC loop residues
Asp270 and Pro271 is also clear.(Ala–Pro in IgG1, Ser–Ser in IgG4), while values for
Ser324, Asn325, Leu328 and Pro329 (all of which
are conserved in IgG) are comparable. That some
local structural aspects of the loop are retained
implies that these key amino acid differences
between IgG1 and IgG4, Pro331Ser and Ala327Gly,
both of which introduce conformational flexibility into
the loop, are responsible. The adjacent BC loop is,
unsurprisingly, affected by the FG loop changes, and
residues 270–272 also adopt a different conforma-
tion in IgG4 (Fig. 3).
The FG loop conformation in IgG4 is not an
artefact of crystal packing. Despite their different
packing environments, the conformation is the
same in both chains. While an IgG1-like confor-
mation in chain B would clash due to crystal
contacts, in chain A, the FG loop is free to adopt
either conformation.
CH2 domain FG loop conformation modulates
the Fcγ receptor interaction
The FG loop in the CH2 domain is a major
determinant of FcγR binding in IgG1 and, together
with residues of the lower hinge region, constitutes
one of two sub-sites. Pro329 forms a hydrophobic
“proline sandwich” with two tryptophan residues in
the receptor, a feature seen in both IgG1-FcγRII
[22] and IgG1-FcγRIII [23–26] crystal structures,
and the same interaction is conserved (with
Pro426) in the IgE-FcεRI complex [49]. The FG
loop conformation in IgG4-Fc shifts the position of
Pro329 considerably (Fig. 4a). In IgG1, the two
sites of receptor engagement, along with the lower
hinge region, bury a surface area of ~1620 Å2
(~1170 Å2 without the lower hinge region). In
moving away from the CH2 domain, the different
FG loop conformation in IgG4 is unable to contact
the receptor, with the loss of ~150 Å2 buried
surface area from the interface.
CH2 domain FG loop conformation alters the
C1q binding site
In human IgG1, residues Asp270 (BC loop),
Lys322 (strand F), and Pro329 and Pro331 (FG
loop) have been implicated in C1q binding
[19,50,51]. In IgG4, the position of the conserved
Lys322 is the same as in IgG1, but Ser331 replaces
Pro331 (Fig. 4a), and although conserved, both
Asp270 and Pro329 occupy very different positions
due to the unique conformation of the FG loop, and
the effect that this has upon the adjacent BC loop
(Figs. 3 and 4b).
Comparison of the FG loop sequences of human
IgG1–IgG4 (Fig. 4c) indicates that a striking, and
distinguishing feature of IgG4 in this region, is the
Pro to Ser replacement at position 331. Indeed, its
role in complement binding has been reciprocally
635Crystal structure of Human IgG4-Fcdemonstrated experimentally: the mutation Ser331-
Pro in IgG1 and IgG3 reduces C1q binding [19,50],
while the Pro331Ser mutation partially restores C1q
binding to IgG4 [50,52]. However, an IgG4-like FG
loop conformation was not observed in an IgG1-Fc
crystal structure containing the Pro331Ser mutation,
as crystal packing precluded the formation of such a
loop structure [53].
No contact predicted between the CH2 FG loop
and the lower hinge/CH2 domain junction
The lower hinge is not always fully ordered in
IgG1-Fc crystal structures, but Pro238, at the
junction with the CH2 domain, forms van der Waals
interactions with Leu328 from the CH2 FG loop. In
the few crystal structures of whole IgG reported to
date, residues of the FG loop are found to interact
with residues close to, or within, the lower hinge
(residues 231–237), although the extent of interac-
tion varies due to conformational asymmetry in the
crystals. In human IgG1 [32], Leu328 and Pro329
from the FG loop form van der Waals contacts with
Gly236 and Pro238 on one chain, and Leu235 and
Pro238 on the other. In mouse IgG2 [54], one chain
has limited contact between the FG loop and the
lower hinge region, but in the other, the two are
intimately associated, with Leu328, Pro329 and
Ala330 contacting Pro232, Asn233, Leu235 and
Pro238. In whole IgG4, the altered FG loop
conformation would preclude any contact with either
the lower hinge region or Pro238, with potential
structural and functional implications.Discussion
Overall structure
The structures reported here of recombinant (rFc)
and serum-derived (sdFc) IgG4-Fc represent the
first high-resolution crystal structures for this anti-
body subclass. The overall structure of the Fc
fragment is similar to that already reported for the
highly homologous IgG1 and IgG2 subclasses, but
unique structural features of IgG4-Fc have now
been revealed.
Implications for FAE
The rFc and sdFc IgG4 structures have revealed
how Arg409 can adopt two different conformations,
each of which affects the CH3 interface differently.
While conformation 1 is similar to that seen in IgG1
structures, conformation 2 weakens the interface by
disrupting the water structure. With the exception of
chain B of the sdFc structure where Arg409 is
disordered, Arg409 adopts conformation 1 in threechains (PDB ID 1ADQ [37]; rFc chain A and sdFc
chain A) and conformation 2 in three chains (PDB ID
4B53; chains A and B [17] and rFc chain B). Only
conformation 2 was observed in the CH3 domain
crystal structure, but overall, the two Arg409
conformers are equally populated.
Intriguingly, the high B-factors for residues at
the CH3 domain surface, and partial disorder at
the CH3 interface in chain B of the sdFc
structure, may represent the transition of
Arg409 between the two conformations, or may
even provide an early snapshot of the dissocia-
tion process itself.
The altered CH2 domain FG loop conformation
may also play a role in FAE. Isomerisation from inter-
to intra-chain disulfide bonds in the hinge region are
believed to be a prerequisite for this process, and
may be facilitated by flexibility in the core hinge,
arising from a Pro (IgG1)/Ser (IgG4) substitution at
position 228. The IgG4 CH2 FG loop precludes any
contact with the lower hinge, and a more mobile
lower hinge could in turn enhance flexibility in the
core hinge.
Low-angle X-ray solution scattering data for whole
IgG4 revealed a change in overall structure from a
symmetric shape to an asymmetric shape when
Ser331 from the CH2 FG loop was mutated to proline
[35]. Given the potential for contact between the
lower hinge and the FG loop, it is thus possible that
overall antibody structure, and function, might be
linked to the FG loop conformation.
Fc–Fc interfaces I and II utilise conserved
“consensus binding site” residues
Analysis of interfaces between IgG-Fc and vari-
ous protein binding partners, FcRn [46], rheumatoid
factor [37], protein A [27] and protein G [28], led to
the identification of a common “consensus binding
site” comprising residues Met252, Ile253, Ser254,
Asn434, His435 and Tyr436, from both CH2 and
CH3 domains, located on the side of IgG-Fc [18].
Both interfaces I and II utilise these consensus
residues: interface I incorporates residues 254, 434
and 436, while interface II incorporates residue 253.
In the IgG4-Fc crystals, both interfaces I and II exist
simultaneously; that is, one Fc chain utilises the
consensus site to engage two others.
Interfaces I and II share similarities with consensus
site residue interactions. In interface II, a hydrogen
bond is formedwith the backboneof Ile253, as in FcRn,
rheumatoid factor, protein A and protein G interactions.
Additionally, in interface II, Ile253 is surrounded by
Gln268,Glu294andTyr300, similar to the interfacewith
FcRn (Glu135, Trp133) and protein A (Gln128,Gln129,
Phe132). In interface I, Ser254 forms van der Waals
interactions with Tyr436, similar to the interface with
protein G (Ser254/Tyr45) and rheumatoid factor
(Ser254/Trp52A). Thus, interfaces I and II share
636 Crystal structure of Human IgG4-Fcgenerally conserved features of interfaces between
IgG and a variety of protein binding partners. (While
not forming part of the consensus site, Leu309 is alsoa contact residue for protein A [27] and rheumatoid
factors [55] and, in IgG4, is the site of a leucine/valine
isoallotypic variation [56].)
637Crystal structure of Human IgG4-FcResidues from Fc–Fc interface II belong to
aggregation-prone “motifs”
A recent computational approach identified hydro-
phobic “motifs” in IgG1 CH1, CH2 and CH3 domains
and hinge region, which are prone to aggregation
[42]. Motifs involving residues Ile253, Tyr296
(Phe296 in IgG4) and Leu309, all involved in IgG4
Fc–Fc interface II, were among those identified in the
study. The same authors found that mutating certain
hydrophobic residues, for example, Ile253 and
Leu309, to a hydrophilic lysine, indeed improved
antibody stability [57].
Interfaces I and II provide clues about
antibody–antibody interactions
With a buried surface area of 1480 Å2, Fc–Fc
interface I, observed in both IgG1 and IgG4, is
comparable with those for Fc binding to the
neonatal IgG receptor, rheumatoid factor, protein
A, protein G, FcγRIII and HSV-1 receptor (which
range from 1350 Å2 to 2000 Å2). IgG4 Fc–Fc
interface II is smaller (860 Å2), but could form
under certain conditions such as high concentra-
tion. IgG Fc–Fc interactions have been document-
ed in vitro [58], and in vivo in diseases such as
rheumatoid arthritis [6] and auto-immune pancrea-
titis [7], where IgG4 antibody levels are elevated
[6], and there is also some evidence that thera-
peutic monoclonal IgG4 antibodies have a higher
tendency to aggregate, compared with IgG1 [44].
However, the equivalent residue to Phe296 from
IgG4 is Tyr296 in IgG1, suggesting that a similar
interface could also form in this subclass. The
concentrations required for therapeutic antibodies,
which include both IgG1 and IgG4 [41], may
promote such an interaction.
Assemblies using a whole antibody structure [54]
as a template can be generated using IgG4-Fc
interfaces I and II, in a manner that can also
accommodate both Fab regions (Fig. 2c and d,
Fig. S2). Novel interfaces, such as those observed
in human IgG4, and previously described for mouse
IgG2 [48], may therefore indeed be relevant to
understanding, and thus preventing, aggregation of
whole IgG antibodies.Fig. 4. Unique conformation of the CH2 FG loop in IgG4
structure (green) on that of IgG1-Fc bound to FcγRIII (grey) (P
the FG loop in IgG4 cannot interact with receptor through
residues 325 and 328 are not shown. (b) Surface views of
highlighting residues important for C1q binding to IgG. The p
significantly altered, while that of Pro/Ser331 (cyan) is not. Asp2
coloured in accordance with a proposedmodel of the IgG-Fc/C1
IgG4 and IgE for residues comprising the FG loop. The cons
binding is highlighted in blue. With the exception of IgG4, all o
(yellow) near the proline involved in receptor binding. IgG2 and
327 (green).The CH2 FG loop conformation is unique to IgG4
A DALI structural similarity search [59] of the PDB,
using IgG4-Fc as the search term, returned over 150
hits for immunoglobulin heavy chains, including IgG
(human, rabbit, mouse, rat), IgE (human), IgA
(human), IgY (chicken) and IgM (mouse) isotypes.
In the structures of IgG and IgE, isotypes known to
engage receptor through a “proline sandwich”
interaction, the conformation of the Cγ2 and Cε3
domain FG loop was broadly similar to that found in
IgG1, despite crystal packing in the majority of cases
that would allow an IgG4-like conformation to be
adopted. In only a few heavy chains were slightly
different FG loop conformations found, and with the
exception of an IgG2 mutant, discussed below, none
were similar to that found in IgG4, and the relative
position of receptor binding Pro329 (Pro426 in IgE)
was unaffected. The structural conservation of the
FG loop conformation in IgG1 and IgE thus reflects
its role in receptor binding. However, in an IgG2-Fc
mutant, in which Ala330 and Pro331 were both
mutated to serine [34], the FG loop adopts a
conformation similar to that found in IgG4. Since
IgG2 naturally has a glycine at position 327 (Fig. 4c),
these two additional mutations essentially recreate
the IgG4 CH2 FG loop in IgG2.
We next examined FG loop conformation in the
other immunoglobulin isotypes returned by the DALI
search. IgA engages FcαRI at a site located at the
Cα2–Cα3 interface, and not through the Cα2 domain
FG loop, and the structurally equivalent residue to
the receptor binding proline in IgG1 and IgE is lysine
[60]. Nevertheless, despite this key difference, and
some local perturbation about the lysine residue, the
overall conformation is essentially similar to the CH2
and Cε3 domain FG loops in IgG1 and IgE,
respectively. Structural conservation of the Cα2 FG
loop, discussed below, is attributed to two proline
residues, which flank the loop on either side.
Less is known about the interactions between IgY
and IgM and their receptors. IgY, found in birds and
reptiles, engages one receptor, CHIR-AB1, at the
Fcυ3–Fcυ4 domain interface [61,62]. The Fcυ3
domain FG loop was later identified as a binding
site for a second receptor, ggFcR [63]. The
conformation of the IgY Fcυ3 domain FG loop is-Fc. (a) Superposition of the recombinant IgG4-Fc (rFc)
DB ID 1E4K [23]) reveals how the different conformation of
the proline sandwich (Trp87-Pro329-Trp110). For clarity,
IgG1-Fc (PDB ID 3AVE [21]) (left) and IgG4-Fc (right)
ositions of residues Asp270 (pink) and Pro329 (blue) are
70 from chain A, and Pro329 and Ser331 from chain B, are
q interaction [51]. (c) Sequence alignment of human IgG1–
erved proline (329 in IgG/426 in IgE) involved in receptor
ther FG loop sequences contain a second proline residue
IgG4 are the only sequences containing glycine at position
Fig. 5. The CH2 FG loop and Fcγ receptor binding via the proline sandwich. (a) IgG1 FG loop (orange) forms a proline
sandwich with FcγRIII (yellow) (PDB ID 1E4K [23]). (b) IgG4-Fc (grey) superposed onto IgG1-Fc from PDB ID 1E4K
demonstrates that the proline sandwich interaction with FcγRIII (yellow) is disrupted, and there would be no interaction
between the IgG4 FG loop and FcγRIII.(c) Comparison with the structure of IgG1 in complex with FcγRII (PDB ID 3RY6
[22]) reveals that there would be no interaction between the IgG4 FG loop (grey) and FcγRII (green). (d) Superposition of
IgG4-Fc (grey) onto IgG1-Fc from PDB ID 1E4K, and FcγRI (pink) (PDB ID 3RJD [70]) superposed onto FcγRIII from PDB
ID 1E4K, reveals that, with a change in conformation, Arg102 could form two hydrogen bonds, indicated with black lines,
with Pro329 and Ser330 from the IgG4 FG loop. The hydrogen bond with Pro329 is preserved in IgG1 and IgG4/FcγRI
interactions while that with Ser330 is unique to IgG4. The conformation of Arg102 found in the FcγRI structure is shown in
pink, and the modelled conformation is in grey.
638 Crystal structure of Human IgG4-Fcessentially identical to that found in IgG1 and IgE
[64], and the position of Pro439, equivalent to
Pro329 (IgG) and Pro426 (IgE), suggests engage-
ment in a manner similar to that of IgG/FcγR and IgE/
FcεRI. The recently published NMR structure of the
mouse IgM Fcμ3 domain also revealed an FG loopwith a similar conformation to those found in IgG1,
IgE and IgY [65]. Thus, to the best of our knowledge,
among native antibody isotypes, the IgG4 CH2 FG
loop adopts a unique conformation.
A common feature of these structurally conserved
FG loops is the presence of two proline residues. In
639Crystal structure of Human IgG4-FcIgG, IgE, IgY and IgM, the first, receptor binding (or
putative receptor binding), proline residue is found at
position 329, 426, 439 and 312, respectively. IgG,
IgY and IgM have a second, structurally equivalent
proline residue at position 331, 441 and 314,
respectively. In IgE, this residue is alanine, and a
second proline residue is instead found at position
423. IgA does not have a receptor binding proline
residue, and the overall conformation of the Cα2 FG
loop is instead maintained by two flanking proline
residues. On one side of the loop, Pro333 is
structurally equivalent to Pro331 from IgG1, Pro441
from IgY and Pro314 from IgM, while on the other,
Pro328 is structurally equivalent to Pro423 from IgE.
IgG4 does not have a second proline residue located
within the CH2 domain FG loop, and the implications
of this are discussed later.
Does the CH2 FG loop modulate receptor
binding in IgG4?
A strictly conserved feature of the CH2 domain FG
loop in IgG is a proline residue at position 329, which is
important not only for receptor interaction, but also for
C1q binding (Fig. 4c). In IgG1, mutation of Pro329 to
alanine alone significantly reduces binding to all Fcγ
receptors and C1q [19,66]. In IgG3, mutation of
Pro331 to serine reduces affinity for receptor [67].
The disrupted proline sandwich interaction, caused by
the different CH2 FG loop conformation, is certainly
consistent with the lower affinity of IgG4 for FcγRIIa
(KA of 1.7 × 10
5 M−1 and 2.1 × 105 M−1 for theH131
and R131 variants, respectively) and FcγRIIIa (KA of
2.0 × 105 M−1 and 2.5 × 105 M−1 for the F158 and
V158 variants, respectively), compared with IgG1 [KA
values of 5.2 × 10 6 M − 1 (FcγRIIa, H131),
3.5 × 106 M−1 (FcγRIIa, R131), 1.17 × 106 M−1
(FcγRIIIa, F158) and 2.0 × 106 M−1 (FcγRIIIa,
V158)] [2]. Modelling of the IgG4-Fc structure onto
the crystal structures of the IgG1-Fc complexes with
FcγRII and III illustrates this clearly (Fig. 5a–c).
However, interaction between IgG4 and the lower
affinity FcγRII and FcγRIII receptors is further
complicated by differences between receptor vari-
ants. While IgG4 binds FcγRIIIa, it does not bind
FcγRIIIb [2]; residues for these two receptors are
identical in the immediate vicinity of the proline
sandwich, and the contrasting affinity is attributed to
sequence differences at positions 147 and 158 [2];
critically, position 147 is located at the second
receptor binding sub-site on the other CH2 domain.
Furthermore, IgG4 binds FcγRII receptors with lower
affinity, but FcγRIIb is bound with higher affinity than
FcγRIIa [2]. An arginine residue is found at position
131 in FcγRIIb, whereas in FcγRIIa, the equivalent
residue is histidine. Incidentally, an arginine/histidine
difference at this position is also responsible for the
high- and low-responder forms of FcγRIIa [68]. Of
the FcγRII receptor variants, the low-responder formof FcγRIIa, with histidine at position 268, is bound
by IgG4 with the lowest affinity. Intriguingly, in the
IgG1-Fc/FcγRIIa crystal structure, Arg131 from the
receptor lies close to residue 268 from the BC loop
[22], which is histidine in IgG1 and glutamine in IgG4.
If Arg131 were to adopt a different conformation, the
higher affinity of IgG4 for FcγRII variants with
arginine at this position could, in part, be explained
by a hydrogen bond with Gln268 from the BC loop.
The affinity of IgG4 for FcγRI is not only higher than
that for FcγRII and FcγRIII, but of the same order of
magnitude as that for IgG1 (KA of 6.5 × 10
7 M−1 and
3.4 × 107 M−1 for IgG1 and IgG4, respectively) [2]. In
contrast to FcγRII and FcγRIII, where IgG immune
complexes are responsible for receptor interaction,
monomeric IgG4 is responsible for the interaction with
FcγRI [2,69]. Although there is no crystal structure for
the IgG1-Fc complex with FcγRI, a model based upon
the FcγRI crystal structure has been proposed [70],
and if IgG4-Fc is substituted for IgG1-Fc in thismodel, a
hydrogen bond, additional to that between Arg102 and
Pro329 (main chain), may bemade betweenArg102 of
FcγRI (which is unique to this receptor) and Ser330
(side-chain) in the FG loop conformation of IgG4
(Fig. 5d).
Could the additional hydrogen bond between
Arg102 and Ser330 side chains compensate in the
absence of a proline sandwich in the IgG4/FcγRI
receptor interaction, allowing IgG4 to bind with an
affinity comparable to that of IgG1? The FcγRI
crystal structure suggested that the presence of a
tyrosine residue at position 176 in FcγRI, rather than
the structurally equivalent valine in FcγRIII, created
an additional hydrogen bond between FcγRI and the
lower hinge that could account for the difference in
isotype specificity and, therefore, affinity, between
FcγRI and FcγRIII for IgG4 [70].
In summary, the altered CH2 FG loop conformation
in IgG4 cannot solely account for the differences in
affinity between IgG4 and Fcγ receptors, but confor-
mational variation in the loop may act together with
sequence differences between the Fcγ receptors, in
addition toalternative interactionswith the lower hinge,
to modulate IgG4 affinity. It remains to be determined
whether, unaffected by crystal packing restrictions, the
native IgG4 loop could also adopt the conserved
IgG1-like conformation, potentially adding a further
level of complexity in control of receptor affinity.
Which residues are responsible for the different
CH2 FG loop conformation in IgG4?
Point mutations have confirmed the role of FG loop
residues in controlling IgG function, and two de-
cades ago it was speculated that sequence variation
in this region might affect FG loop conformation [71].
IgG4 does not possess a second proline residue in
its FG loop (Fig. 4c) and Pro331 is replaced by
serine. Furthermore, IgG4 is different from IgG1,
Table 1. Data processing and refinement statistics.
Recombinant Fc (rFc) Serum-derived Fc (sdFc)
Data processing
Space group P212121 P212121
Unit cell dimensions
a, b, c (Å) 74.84, 78.97, 97.88 74.29, 80.74, 99.19
Resolution (Å) 74.84–1.90 (1.94–1.90)a 80.74–2.35 (2.45–2.35)a
No. of unique reflectionsb 46,409 (2957)a 25,471 (2828)a
Completeness (%)b 99.9 (99.9)a 99.7 (99.9)a
Multiplicityb 14.4 (14.4)a 10.7 (11.2)a
Mean [(I)/σ(I)]b 16.7 (2.1)a 14.4(1.6)a
Rmerge (%)
b 10.6 (154.5)a 10.0 (225.9)a
Rpim (%)
b 2.9 (42.1)a 3.2 (69.6)a
Wilson B-factor (Å2) 26.9 56.9
Refinement
Rwork/Rfree (%) 17.01/20.86 18.79/23.81
RMSD
Bond lengths (Å) 0.013 0.009
Bond angles (°) 1.490 1.123







Protein: CH2 A/B 32.96/46.16 55.2/76.4
Protein: CH3 A/B 33.28/33.04 61.84/67.8






a Numbers in parentheses are for the highest resolution shell.
b Data scaled with Aimless [74].
c Includes alternative positions.
d Ethylene glycol and MES buffer.
e Ramachandran plot generated by MolProbity [78].
640 Crystal structure of Human IgG4-FcIgG3 and IgE in that, like IgG2, it has a glycine
residue located within its FG loop, at position 327. The
crystal structure of IgG2-Fc revealed no effect on FG
loop conformation due to packing constraints [33].
Likewise, the structure of an IgG1-Fc mutant engi-
neered to remove effector functions, containing a
Pro331Ser mutation, revealed no effect on the FG
loop, but once again, steric restrictions due to crystal
packing precluded formation of an IgG4-like FG loop
conformation [53].
A recent structural study of an IgG2-Fc mutant [34]
led to the suggestion that the altered position of Pro329
ultimately resulted from disruption of an electrostatic
interaction between His268 and Glu294 at the CH2
domain surface. However, this particular electrostatic
interaction shows inter-species variation and, even in
human IgG, doesnot always form.When the interaction
is not formed, when the BC loop is disordered, or
indeed in one structure, conformationally different, the
conformation of the FG loop is not affected.
We have revealed the structure of the CH2 FG loop
in native IgG4-Fc, unaffected by crystal packing, andinstead propose that conformational differences
between the IgG4 CH2 domain FG loop and that of
IgG1 are due to the introduction of conformational
flexibility through the presence of Gly327 and
Ser331. Further structural data will be required to
establish the essential residues that determine the
FG loop conformation that we have observed.
Conclusions
The first high-resolution structures for IgG4-Fc
reported here have shed light on the unique
functional features of this human antibody subclass.
Variations in conformation at the CH3–CH3 interface
involving Arg409 indicate how this residue, unique to
IgG4, may destabilise interaction between the heavy
chains and contribute to FAE. The FG loop in the
CH2 domain of IgG4 is also seen to adopt a
conformation distinct from that which is common to
all other IgG subclasses and antibody classes (IgA,
IgM, IgY); since this loop plays a key role in receptor
and complement interactions, the non-inflammatory
641Crystal structure of Human IgG4-Fcproperties of IgG4 may now be understood. This
conformation also precludes potentially stabilising
interactions with the hinge region, which may further
promote FAE. Finally, extensive intermolecular (crystal
packing) contacts, including one interaction not previ-
ously observed in other IgG-Fc structures, may explain
the tendencyof IgG toaggregate. These results all have
implications not only for the engineering of therapeutic
monoclonal antibodies, but also for understanding the
role of IgG4 antibodies in disease pathology.Materials and Methods
Protein production
Serum-derived (sdFc) and recombinant (rFc) IgG4-Fc
were prepared as described previously [39,58]. Both
proteins were dialysed into 20 mM Tris–HCl pH 8.
Crystallisation
Crystals of both rFc and sdFc were grown at 291 K
using a reservoir comprising 100 μL of 100 mM 4-mor-
pholineethanesulfonic acid (MES) pH 6.5, 18–20% (w/v)
polyethylene glycol 10,000, and protein concentrations of
3 mg/mL and 2.5 mg/mL, respectively. Drop sizes were
100 nL protein and 100 nL reservoir, and 300 nL protein
and 300 nL reservoir, for the rFc and sdFc crystals,
respectively. Crystals typically appeared after 2 days and
were briefly cryoprotected in a solution of 100 mM MES
pH 6.5, 20% (w/v) polyethylene glycol 10,000 and 20%
(v/v) ethylene glycol before flash-cooling in liquid
nitrogen.This is an open-access article distributed under the terms of
the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in anyData processing, structure determination and
refinement
Data were collected at beamline I03 at the Diamond
Light Source (Harwell, UK). Integration was performed with
XDS as implemented in the xia2 package [72,73], and
further processing was carried out using the CCP4 suite
[74]. Both structures belong to space group P212121, with
one molecule in the asymmetric unit, and were solved by
molecular replacement using MOLREP [75]. The rFc
structure (1.9 Å resolution) was solved using IgG4-Fc
protein atoms from PDB ID 1ADQ [37] as a search model,
and the sdFc structure (2.35 Å resolution) was solved
used a partially refined recombinant IgG4-Fc structure.
Refinement was performed with PHENIX [76], and manual
model building was performed with Coot [77]. Carbohy-
drate residues were refined with 100% occupancy. 5% of
reflections were assigned to the Rfree reflection set using
PHENIX, and TLS groups were assigned with PHENIX.
Overall structure quality was assessed with MolProbity
[78] and POLYGON [79] within PHENIX, and carbohydrate
was assessed using CARP [80]. The final Rwork/Rfree
values were 17.01%/20.86% and 18.80%/23.94% for the
rFc and sdFc structures, respectively. Full data processing
and refinement statistics are provided in Table 1. For
consistency, all buried surface area calculations wereperformed with CNS [81] using protein atoms only from
entries available from the PDB. Figures were produced
with PyMOL (The PyMOL Molecular Graphics System,
Version 1.1r1, Schrödinger, LLC).
Accession numbers
Coordinates and structure factors have been deposited
at the PDB with IDs 4C54 and 4C55 for the rFc and sdFc
structures, respectively.Acknowledgements
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